This company has been marked as potentially delisted and may not be actively trading. Viracta Therapeutics (VIRX) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Viracta Therapeutics (NASDAQ:VIRX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage10.69%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$25.53KNumber OfInsiders Selling(Last 3 Years)2Amount OfInsider Selling(Last 3 Years)$39.63K Get VIRX Insider Trade Alerts Want to know when executives and insiders are buying or selling Viracta Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIRX Insider Buying and Selling by Quarter Viracta Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/27/2024Daniel R ChevallardCFOSell3,405$0.73$2,485.65 11/30/2023Mark RotheraCEOBuy52,094$0.49$25,526.06 11/28/2023Daniel R ChevallardCFOSell3,720$0.50$1,860.00 8/28/2023Daniel R ChevallardCFOSell3,512$1.45$5,092.40 5/25/2023Daniel R ChevallardCFOSell3,635$1.42$5,161.70 2/27/2023Daniel R ChevallardCFOSell3,599$1.68$6,046.32 2/27/2023Lisa RojkjaerInsiderSell2,156$1.68$3,622.08 11/28/2022Daniel R ChevallardCFOSell3,532$2.72$9,607.04 11/28/2022Lisa RojkjaerInsiderSell2,116$2.72$5,755.52 (Data available from 1/1/2013 forward) VIRX Insider Trading Activity - Frequently Asked Questions Who is on Viracta Therapeutics' Insider Roster? The list of insiders at Viracta Therapeutics includes Daniel R Chevallard, Lisa Rojkjaer, and Mark Rothera. Learn more on insiders at VIRX. What percentage of Viracta Therapeutics stock is owned by insiders? 10.69% of Viracta Therapeutics stock is owned by insiders. Learn more on VIRX's insider holdings. Which Viracta Therapeutics insiders have been buying company stock? The following insider purchased VIRX shares in the last 24 months: Mark Rothera ($25,526.06). How much insider buying is happening at Viracta Therapeutics? Insiders have purchased a total of 52,094 VIRX shares in the last 24 months for a total of $25,526.06 bought. Which Viracta Therapeutics insiders have been selling company stock? The following insider sold VIRX shares in the last 24 months: Daniel R Chevallard ($4,345.65). How much insider selling is happening at Viracta Therapeutics? Insiders have sold a total of 7,125 Viracta Therapeutics shares in the last 24 months for a total of $4,345.65 sold. Viracta Therapeutics Key ExecutivesMr. Mark Andrew Rothera (Age 61)CEO, President & Director Compensation: $365.03kDr. Susan Perrine M.D.Scientific Founder and ConsultantDr. Ronald J. Berenson M.D. (Age 72)Co-Founder and Consultant Mr. George HillmanCo-FounderDr. Thalia Papayannopoulou M.D.Co-FounderDr. Robert M. Williams Ph.D. (Age 69)Co-Founder Dr. Douglas V. Faller M.D.Ph.D., Scientific Founder & Chairman of Scientific Advisory BoardMs. Melody Burcar CPA (Age 41)M.B.A., Senior VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer Dr. Ayman El-GuindyChief Scientific OfficerMr. Stewart M. BrownSenior VP of Legal Affairs & General Counsel More Insider Trading Tools from MarketBeat Related Companies GRTX Insider Selling NMTR Insider Selling HEPA Insider Selling VINC Insider Selling ORGS Insider Selling PBLA Insider Selling SMFL Insider Selling EVLO Insider Selling AMPE Insider Selling CMRA Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Marvell Insiders Buy Shares—Should Investors Follow Suit?This Insider Just Made a Massive Bet on Transocean's ComebackInsider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?Oklo Insiders Sell! Oh No! This Is Why Investors Shouldn’t WorryTop Insider Buys and Sells From September: Buy, Sell, or Hold? This page (NASDAQ:VIRX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
